多西紫杉醇联合卡培他滨在进展期胃癌中的疗效观察

目的：探讨多西紫杉醇联合卡培他滨在进展期胃癌中的疗效。方法：选取2007年1月~2010年12月于本院进行化疗的140例进展期胃癌患者为研究对象,将其随机分为对照组（奥沙利铂、亚叶酸钙联合氟尿嘧啶组）70例和观察组（多西紫杉醇联合卡培他滨组）70例,后将两组患者治疗2个周期的总有效率及不良反应发生率进行统计及比较。结果：观察组的治疗总有效率（77.14%）明显高于对照组（54.29%）,而不良反应发生率（恶心呕吐为51.43%,骨髓抑制为34.29%,其他为22.86%）却低于对照组（恶心呕吐为68.57%,骨髓抑制为34.29%,其他为22.86%）,P均〈0.05,差异均有统计学意义。结论：多西紫杉醇联合卡培他滨在进展期胃癌中的疗效较好,安全性也较受肯定,较为可取。

The effect observation of docetaxel combined with capecitabine in advanced gastric cancer

Objective：To study the effects of docetaxel combined with capecitabine in advanced gastric cancer.Methods：140 patients with advanced gastric cancer in our hospital from January 2007 to December 2010 were selected as research object,and they were randomly divided into control group（oxaliplatin,calcium folinate combined with fluorouracil group） 70 cases and observation group（docetaxel combined with capecitabine group） 70 cases,then the total effective rate and incidence of adverse reactions of two groups after 2 cycles were analyzed and compared.Results：The total effective rate of observation group（77.14%） was higher than that of control group（54.29%）,incidence of adverse reactions（nausea and vomiting was 51.43%,myelosuppression was 34.29%,other was 22.86%） was lower than that of control group（nausea and vomiting was 68.57%,myelosuppression was 34.29%,other was 22.86%）,all P〈0.05,there were all significant differences.Conclusion：The effects of docetaxel combined with capecitabine in advanced gastric cancer is better,security is affirmed,and it is retrievable.